

P1520

**Management and outcome of women with NSTEMI. Have there been any changes in recent years?**

C. Cacho, T. Gonzalez Ferrero, A. Torrelles Fortuny, M. Perez Dominguez, C. Abbou Johk, P.J. Antunez Muinos, B. Alvarez Alvarez, R. Agra Bermejo, P. Rigueiro Veloso, J.M. Garcia Acuna, J.R. Gonzalez Juanatey

*University Hospital of Santiago de Compostela, Santiago de Compostela, Spain*

**Introduction:** Women have been less represented in every NSTEMI clinical trial. Moreover, it has been observed that this group of patients have usually received less revascularization and evidence based treatment, therefore presenting with a greater long and short-term mortality.

**Purpose:** The purpose of our study is to analyze the presence of differences in baseline characteristics, management and outcome of women with NSTEMI during the last decade.

**Methods and results:** Retrospective study including 861 women admitted for NSTEMI between 2003 and 2015 in our center. We divided 2 groups according to hospitalization period (2003–2008 and 2009–2015) with a medium follow up of 4.5±2.9 years. Baseline characteristics and treatment at discharge are described on table 1. We noticed a greater use of statins

and ACEI/ARB on the second period as well as a greater percentage of patients receiving early revascularization. It is remarkable on women a non-significant reduction of heart failure hospitalization at follow up (6.8% vs 4.5%;  $p=0.091$ ), neither differences on 30-day mortality (1.3% vs 0.4%) or 1-year mortality (7.1% vs 5.8%). However, long-term mortality for the second group is reduced (HR 0.69; CI 95% 0.52–0.89), even after performing a multivariate analysis (HR 0.64; CI 95% 0.48–0.85).

**Conclusions:** In recent years, early interventionist management and greater use of evidence-based therapies have been observed in women with NSTEMI. This has been associated with a lesser long-term mortality, although short-term events have remained the same.

Characteristic	Population (n=861)	2003–2008 (n=395)	2009–2015 (n=466)	p-value
Age (years)	73±12	73±12	72±12	0.316
Hypertension	629 (73.1%)	285 (72.2%)	344 (73.8%)	0.318
Hypercholesterolemia	414 (48.1%)	190 (48.1%)	224 (48.1%)	0.523
Killip class				0.292
I	664 (77.1%)	299 (75.7%)	365 (78.3%)	
II	143 (16.6%)	74 (18.7%)	69 (14.8%)	
III	47 (5.5%)	20 (5.1%)	27 (5.8%)	
IV	4 (0.5%)	2 (0.5%)	2 (0.4)	
GRACE score	129±32	130±37	128±33	0.897
Early PCI	249 (29.3%)	76 (19.2%)	173 (38.0%)	<0.005
Treatment at discharge				
AAS	698 (81.1%)	313 (79.2%)	385 (82.6%)	0.120
Clopidogrel	465 (54.0%)	221 (55.9%)	244 (52.4%)	0.162
ACEI/ARB	466 (54.1%)	191 (48.4%)	275 (59.0%)	0.001
Beta-blocker	509 (59.1%)	238 (60.3%)	271 (58.2%)	0.290
Statins	643 (74.7%)	275 (69.6%)	368 (79.0%)	0.001